Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 10/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | USP2 | O75604 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3951141 | 0.83 | PTGDR2 (0.67) | PTGDR2ALDH1A1NPC1RAB9AHPGD | |
| SCHEMBL3499253 | 0.81 | PTGDR2 (0.59) | PTGDR2TDP1 | |
| SCHEMBL4594627 | 0.81 | PTGDR2 (0.61) | PTGDR2ALDH1A1KDM4ENPC1RAB9A | |
| SCHEMBL4595546 | 0.81 | PTGDR2 (0.68) | PTGDR2HPGDTDP1 | |
| SCHEMBL4200563 | 0.81 | ALDH1A1 (0.66) | PTGDR2ALDH1A1HPGD | |
| SCHEMBL13665133 | 0.80 | ALDH1A1 (0.50) | ALDH1A1KDM4EUSP2NPC1RAB9A | |
| SCHEMBL8905331 | 0.80 | PTGDR2 (0.66) | PTGDR2ALDH1A1TDP1GAASMN1; SMN2 | |
| SCHEMBL13515795 | 0.79 | NPC1 (0.70) | PTGDR2ALDH1A1NPC1RAB9AHPGD | |
| Hydrochloric Acid SCHEMBL8484286 | 0.78 | PTGDR2 (0.64) | PTGDR2ALDH1A1KDM4ETDP1GAA | |
| SCHEMBL10595469 | 0.78 | PTGDR2 (0.59) | PTGDR2ALDH1A1KDM4EUSP2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1489078-B1 | BENZOFURAN DERIVATIVE | MITSUBISHI TANABE PHARMA CORP (JP) | 2010-01-06 | — | — | EP | disclosed |
| US-7605158-B2 | Carbamoyl-type benzofuran derivatives | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-10-20 | — | — | US | disclosed |
| US-20090209511-A1 | Benzofuran Derivatives | KAWAGUCHI TAKAYUKI | 2009-08-20 | — | — | US | disclosed |
| US-7531537-B2 | Benzofuran derivative | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-05-12 | — | — | US | disclosed |
| US-20060247273-A1 | Carbamoyl-type benzofuran derivatives | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2006-11-02 | — | — | US | disclosed |
| EP-1489078-A1 | BENZOFURAN DERIVATIVE | Tanabe Seiyaku Co., Ltd. (JP) | 2004-12-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060247273-A1 | Carbamoyl-type benzofuran derivatives | F12, F2, F3 | PTGDR2 3122/4885ALDH1A1 1153/4885KDM4E 204/4885 |
| US-20090209511-A1 | Benzofuran Derivatives | F12, F2, F3 | PTGDR2 2108/4885ALDH1A1 693/4885KDM4E 1464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.